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Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium
tuberculosis DNA with Higher Levels of Rifapentine Exposure
A. Jayakumar,a R. M. Savic,b C. K. Everett,a D. Benator,c D. Alland,d C. M. Heilig,e M. Weiner,f S. O. Friedrich,g N. A. Martinson,h
A. Kerrigan,i C. Zamudio,j S. V. Goldberg,e W. C. Whitworth,e J. L. Davis,k P. Nahida

The Xpert MTB/RIF assay is both sensitive and specific as a diagnostic test. Xpert also reports quantitative output in cycle
threshold (CT) values, which may provide a dynamic measure of sputum bacillary burden when used longitudinally. We evaluated the relationship between Xpert CT trajectory and drug exposure during tuberculosis (TB) treatment to assess the potential
utility of Xpert CT for treatment monitoring. We obtained serial sputum samples from patients with smear-positive pulmonary
TB who were consecutively enrolled at 10 international clinical trial sites participating in study 29X, a CDC-sponsored Tuberculosis Trials Consortium study evaluating the tolerability, safety, and antimicrobial activity of rifapentine at daily doses of up to
20 mg/kg of body weight. Xpert was performed at weeks 0, 2, 4, 6, 8, and 12. Longitudinal CT data were modeled using a nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time curve [AUC]). The rate of change
of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rifampin. Moreover, rifapentine exposure, but not assigned dose, was significantly associated with rate of change in CT (P ⴝ 0.02). The estimated increase in CT slope
for every additional 100 g · h/ml of rifapentine drug exposure (as measured by AUC) was 0.11 CT/week (95% confidence interval [CI], 0.05 to 0.17). Increasing rifapentine exposure is associated with a higher rate of change of Xpert CT, indicating faster
clearance of Mycobacterium tuberculosis DNA. These data suggest that the quantitative outputs of the Xpert MTB/RIF assay may
be useful as a dynamic measure of TB treatment response.

T

he best available intermediate markers of tuberculosis (TB)
treatment response for individual patient monitoring and
for TB drug development are currently sputum smear microscopy and sputum culture conversion. Sputum culture at intermediate time points, although demonstrated in prior studies to
have some utility for predicting treatment success or failure
(1), has been called into question as a surrogate marker, given
its limited ability to predict relapse (2, 3). Sputum smear microscopy at 2 months, though currently recommended by the
World Health Organization (WHO), has a sensitivity as low as
24% for relapse (4).
The Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA),
an automated, cartridge-based semiquantitative PCR (sqPCR) assay targeting the rpoB locus of Mycobacterium tuberculosis DNA,
received WHO endorsement as a preferred TB diagnostic in 2010
(5, 6). Since endorsement, a massive rollout of Xpert has been
undertaken, delivering the assay to 116 countries, with over 10
million cartridges procured under concessional pricing in the
public sector (5). According to WHO estimates, the costs of
Xpert are similar to those of mycobacterial culture, but largescale implementation of Xpert will not require the infrastructure of specialized laboratories and personnel training needed
for mycobacterial culture technologies (7). Some national TB
programs have already replaced sputum smear microscopy
with Xpert as the primary diagnostic (8–11). It is thus important to determine if there is a role for serial Xpert assays in
monitoring TB treatment response. Previous studies have

3028

jcm.asm.org

demonstrated that the quantitative output of Xpert in cycle
threshold (CT) values, indicating the number of rounds of PCR
amplification required to detect M. tuberculosis DNA, correlates
closely with bacillary burden in sputum in vitro (12). While the
routine Xpert results report includes only a semiquantitative
output (negative, very low, low, medium, high), the numerical
CT also may be obtained from the GeneXpert platform by an
algorithm without additional software. A recent study evaluating the longitudinal use of Xpert in clinical trial participants on
TB therapy found high sensitivity but very low specificity for
the assay; however, this study interpreted Xpert results as a
dichotomous marker (i.e., M. tuberculosis DNA detected versus
not detected) compared to binary microbiologic measures of TB
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treatment response (i.e., smear and culture results) (13). Another
study found an association between numerical CT and same-day
culture status and with treatment failure (14).
In this study, we evaluated serial Xpert sputum assays over 12
weeks of TB treatment within a cohort of patients enrolled in
Tuberculosis Trials Consortium (TBTC) study 29X, a phase 2 randomized clinical trial comparing dose-escalating rifapentinebased regimens with standard rifampin-based therapy for drugsensitive TB (15). We took advantage of the parent study’s
pharmacokinetic (PK) measures to identify clinical and treatment-related factors associated with Xpert CT trajectory.

TABLE 1 Demographic and clinical characteristics of Xpert study
participants at time of enrollment (n ⫽ 115)

MATERIALS AND METHODS
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No. of
participants

% of
participants

Male

77

67

Age
18–35
36–50
⬎50

54
29
32

47
25
28

HIV infected

8

7

CD4 lymphocyte count (cells/mm3)
⬍50
50–199
200–350
⬎350

1
0
1
6

1
0
1
5

History of smoking

59

51

Body mass index (kg/m2)
⬍16
16–18.5
18.6–25
ⱖ25
Not reported

3
37
60
11
4

3
32
52
10
3

Race
Asian
Black
White
Multiracial
Not reported

3
75
25
2
10

3
65
22
2
9

Cavitation on chest radiograph at enrollment

85

74

Chest radiograph class
No cavities
Cavities, ⬍4 cm in aggregate
Cavities, ⱖ4 cm in aggregate

30
40
45

26
35
39

Treatment arm
Rifampin (10 mg/kg/day)
Rifapentine (10 mg/kg/day)
Rifapentine (15 mg/kg/day)
Rifapentine (20 mg/kg/day)

27
34
25
29

23
30
22
25

Culture negative at week 8
Solid medium
Liquid medium
Both solid and liquid media

89
79
78

77
69
68
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Study sites, population, and treatments. Of the 20 international sites
participating in TBTC study 29X (ClinicalTrials registration number
NCT00694629), the Xpert substudy consecutively enrolled consenting
participants at 10 sites in 5 countries: Barcelona, Spain; Lima, Peru;
Kisumu, Kenya; Soweto and Cape Town, South Africa; San Francisco,
California, and 4 sites in Texas, United States. Adult (age, ⱖ18 years)
ambulatory patients with smear-positive pulmonary TB participating in
study 29X were enrolled. All participants underwent HIV testing. Participants were randomly assigned to one of four treatment arms, containing
rifapentine at 10, 15, or 20 mg/kg of body weight or rifampin at 10 mg/kg
in addition to isoniazid, ethambutol, and pyrazinamide at standard doses
during the intensive phase. After completing intensive-phase treatment,
participants continued treatment with a conventional continuationphase regimen, typically isoniazid plus rifampin for 4 additional months
(15, 16). Informed consent was obtained from all participants for the parent
trial, and the study was approved by institutional review boards at the Centers
for Disease Control and Prevention and at each participating site. None of the
Xpert data obtained for this substudy were used for clinical decision-making.
Detailed clinical, radiologic, and laboratory-specific information was recorded on standardized case record forms and captured using double data
entry as part of the parent trial. A standardized protocol was developed and
used at all 10 participating sites involved in the longitudinal evaluation of
Xpert. Information regarding the design, conduct, and results of TBTC study
29X has been published previously (15).
Sputum sample collection and processing. Participants provided
sputum samples at time of enrollment (pretreatment) and at weeks 2, 4, 6,
8, and 12 of anti-TB therapy. Per protocol, a single specimen was obtained
at all time points, except for week 8 when two separate specimens were
obtained. Sputum induction was performed for patients unable to expectorate. Laboratory technicians recorded the volume (which ranged to a maximum of 10 ml) and quality of each sputum sample (salivary, mucoid, or
purulent) and then performed decontamination with conventional 1% to 2%
N-acetylcysteine and sodium hydroxide methods (final NaOH concentration, 1% to 2%) (17). Centrifugation was performed for 15 min at 3,000 ⫻ g,
and the resulting pellet was resuspended with a phosphate buffer solution, pH
6.8, to a total volume of 2 to 2.5 ml (17). For smear microscopy, 0.1 ml of the
suspension was used, and 0.2 ml and 0.5 ml were inoculated into solid (Lowenstein-Jensen) and liquid (Bactec mycobacterial growth indicator tube
[MGIT] 960; Becton Dickinson, Sparks, MD, USA) culture media, respectively. The residual sputum pellet was tested with Xpert using the standardized procedures described below.
Xpert MTB/RIF procedure. Following sampling for other microbiological outcomes, 0.5 ml of the resuspension from the residual pellet was
combined with Sample Reagent (SR; Cepheid) in a 1:3 ratio, and 2 ml of
sample in SR were pipetted into an Xpert MTB/RIF test cartridge. The
cartridge was loaded into the instrument, and Xpert testing was performed automatically by instrument and software according to the manufacturer’s recommendations. For the five target probes within the rpoB
sequence, the sqPCR per-probe threshold cycle was archived and converted to tabular format for analysis. The assay was validated with the use
of positive controls (provided by the manufacturer to each participating

Characteristic

laboratory), prepared by spiking with a known M. tuberculosis DNA copy
number, in order to verify the correct performance of the assay for the
various targets.
Statistical analysis. Longitudinal Xpert CT data were modeled using a
nonlinear mixed effects approach and performed in NONMEM version
7.3 (Icon Development Solutions, Ellicott City, MD, USA). The likelihood
ratio test, which compares ⫺2 log likelihood between two nested models,
was used to assess significance. Of the five probe CT values reported for
each assay, the minimum CT value was used in our analysis as recommended by the manufacturer. A likelihood-based method (M3) was implemented to handle upper censoring for sputum samples in which no M.
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tuberculosis DNA was detected (18). For those few patients who had multiple assay results at a single time point other than 8 weeks, replicate data
were retained in our final model to increase precision. Analyses conducted
with the exclusion of these replicates did not affect results. CT trajectories
were best fit by a model, whereas baseline CT and linear rate of change in
CT could be estimated. A baseline model for the control (rifampin) arm
was developed first, followed by the addition of dose-ranging rifapentine
data. Comparative CT changes for rifapentine versus rifampin were modeled as functions of regimen (dose measured in milligrams per kilogram),
dose (600 mg, 900 mg, or 1,200 mg of rifapentine), or drug exposure as
measured by area under the plasma concentration-time curve (AUC),
which was estimated from a population pharmacokinetic model incorporating plasma rifapentine levels measured at a single time point (15).

RESULTS

A total of 786 sputum samples were obtained from 115 consecutively enrolled study participants from weeks 0 to 12 after initiation of TB treatment. Of these specimens, 217 contained no
detectable M. tuberculosis DNA and were subject to upper censoring. The bulk of undetectable specimens occurred toward the end
of the study period; 30% of week 8 samples and 40% of week 12
samples were Xpert negative. Table 1 describes the demographic
and clinical characteristics of the study participants.
Clinical factors affecting CT trajectory. In univariate analysis,
smoking within the past year and disease extent on chest radiograph were the only clinical covariates that had a significant association with Xpert results. Participants reporting any history of
smoking had a lower baseline CT, indicating a higher bacterial
burden at the time of enrollment (P ⬍ 0.01), than those who did
not smoke. There were no subsequent differences in rate of change
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in CT based on smoking status. Subjects with a baseline chest radiograph indicating high disease extent (defined as more than half
of the chest affected by TB) had a lower baseline CT and a lower CT
slope on treatment, indicating higher bacterial burden at baseline
(P ⫽ 0.05) and a slower subsequent rate of change (P ⫽ 0.04);
however, in multivariate analyses, associations between disease
extent on chest radiograph and rate of CT change were no longer
significant.
Treatment arm, drug dose, and drug exposure effects on CT
trajectory. Median baseline CT was estimated in our model to be
19.81 (95% confidence interval [CI],18.64 to 20.98) with 24%
between-subject variability. Figure 1 depicts raw CT results across
treatment arms, highlighting these significant within-subject and
between-subject variabilities. From week 0 to week 12, the median
rate of change in CT for the rifampin arm was estimated to be 0.88
CT/week (95% CI, 0.61 to 1.14). Comparing participants who received rifampin-based therapy with all of those who received rifapentine-based therapy, irrespective of the dosing, a significant difference in CT trajectory was found, with faster M. tuberculosis
DNA clearance in those receiving rifapentine at a median rate of
change of 1.18 CT/week (P ⫽ 0.05). However, the between-subject
variability across all treatment arms was high (coefficient of variation, 102%).
Since the difference in CT trajectory between those who received rifampin and those who received rifapentine may have
been due to the higher dosages of rifapentine administered
during the study, we investigated the direct association of drug
exposure with M. tuberculosis DNA clearance. Using a popula-
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FIG 1 Cycle threshold (CT) trajectories for 115 individual study participants (gray lines) across treatment arms, demonstrating large intrasubject and intersubject variability over time. The estimated mean CT for each treatment arm (colored lines) rises over time, reflecting clearance of M. tuberculosis DNA with
treatment. No significant difference can be seen in overall CT trajectory between treatment arms.

Rifamycin Impacts Sputum M. tuberculosis DNA Clearance

tion pharmacokinetic model developed for the parent trial,
rifapentine exposure (AUC) was derived for each individual
(15). We found that the derived AUC was a significant predictor of the rate of change in CT (P ⫽ 0.02). The estimated increase in CT slope for every additional 100 g · h/ml of rifapentine AUC was 0.11 CT/week (95% CI, 0.05 to 0.17). Figure 2
depicts the positive correlation between CT slope and median
rifapentine AUC. However, CT trajectories did not vary significantly across rifapentine treatment arms (1.34, 1.38, and 1.10
CT/week for rifapentine at 10 mg/kg, 15 mg/kg, and 20 mg/kg,
respectively; P ⫽ 0.25) or across administered dosage groups
(1.19, 1.09, and 1.10 CT/week at 600, 900, or 1,200 mg, respectively; P ⫽ 0.13). Study 29X showed a similar association between treatment and sputum culture conversion in the liquid
culture medium, in which higher rifapentine exposure, but not
treatment arm (weight-based rifapentine dose) or flat rifapentine dose, was significantly associated with faster culture conversion (15). Table 2 shows previously published data by Dorman et al. (15) from their larger parent study data set cohort
alongside our results from our subset of 115 study participants
to demonstrate the consistent significance of rifamycin exposure across monitoring methodologies.
Effects of baseline CT on subsequent rate of change. When
upper-censored data were excluded, a negative correlation coefficient of 0.57 (relative standard error, 15%) was found between
baseline CT and rate of change in CT over 12 weeks, indicating
faster clearance of M. tuberculosis DNA in individuals with higher
baseline M. tuberculosis DNA burdens. However, this effect was no
longer seen when censored data were included.
DISCUSSION

In this study, we have shown that increasing rifapentine exposure
is associated with faster M. tuberculosis DNA clearance, as measured by longitudinal Xpert CT data, over the first 12 weeks of

December 2016 Volume 54 Number 12

TABLE 2 Overall P values for comparisons of Xpert CT slope
obtained in 115 substudy participants as compared to the time to
stable culture conversion on a solid medium and time to stable
culture conversion on a liquid medium in 195 participants in the
parent clinical trial by treatment arm (rifapentine 10, 15, and 20 mg/
kg versus rifampin; rifapentine dose (600 mg, 900 mg, 1,200 mg
versus rifampin); and rifapentine exposure (area under the
concentration time-curve tertiles)

Variable

Xpert CT
slopea
(n ⫽ 115)

Time to stable
culture conversion
on solid mediumb
(n ⫽ 195)

Time to stable
culture conversion
on liquid mediumb
(n ⫽ 195)

Treatment arm
Rifapentine dose
Rifapentine exposure

0.25
0.13
0.02

0.01
0.01
⬍0.001

0.32
0.38
⬍0.001

a
P values were derived using the likelihood ratio test based on the current substudy of
115 patients.
b
P values were reported previously by Dorman et al. in Supplemental Table E7 (in
reference 15) based on parent study cohort.
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FIG 2 Relationship between CT slope and AUC (g · hr/ml) in 115 study
participants. As rifapentine exposure increases, rate of change in CT also increases, indicating faster M. tuberculosis DNA clearance.

therapy. The association found between rifapentine exposure and
longitudinal Xpert CT trajectory is consistent with the biologically
plausible idea that higher serum levels of effective medication lead
to faster bacterial killing and supports the ability of the Xpert
MTB/RIF assay to measure such a relationship. In addition, our
study demonstrates the feasibility of using PK parameters as a
novel alternative to comparing the assay’s predictive performance with intermediate microbiologic outcomes, which can
be unreliable and insensitive for predicting relapse. Interestingly, the results in this substudy mirror the data from the
parent study on the relationship between drug exposure and
culture conversion, suggesting that despite Xpert’s lower specificity for viable mycobacteria, the overall behavior of the assay
is similar to that of sputum culture in longitudinal use (15). We
also found that clinical factors, including smoking status and
radiographic extent of disease were associated with Xpert CT
measurements in a univariate analysis. While these factors were
not retained in our final statistical model based on predefined
criteria, this nonetheless suggests that greater mycobacterial
burden associated with these important clinical features is additionally quantified by the Xpert assay. Finally, we found that
Xpert CT measurements demonstrate a high degree of withinsubject and between-subject variability. Variation in Xpert’s
semiquantitative estimates among sputum samples within the
same acid-fast bacilli grade has been previously described (19).
Such variability is inherent in any quantitative sputum-based
assay in which specimen collection depends on the strength of
the cough, method of induction or expectoration, and many
other clinical factors. Yet, even given this variability, the association between M. tuberculosis DNA clearance and rifapentine
exposure was significant.
We found that a lower CT (corresponding to higher M. tuberculosis DNA load in sputum) at baseline may predict faster clearance over the course of early treatment. The Xpert MTB/RIF technology incorporates a novel filtering mechanism that primarily
allows intact bacilli to be assayed in the sample, yet concerns have
remained regarding the measurement of DNA from nonviable
M. tuberculosis if Xpert is used in patients while on TB treatment.
Our results suggest that the assay may in fact be able to measure
the rapid killing of mycobacteria seen early in treatment. How-
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